Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgro...

por Cottu, Paul, Ring, Alistair, Abdel-Razeq, Hikmat, Marchetti, Paolo, Cardoso, Fatima, Salvador Bofill, Javier, Martín, Miguel, Menon-Singh, Lakshmi, Wu, Jiwen, De Laurentiis, Michelino
Publicado 2022

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populati...

por De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, Zamagni, Claudio
Publicado 2021

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an ex...

por De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, Zamagni, Claudio
Publicado 2021